Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA
Helsinki, Finland: 27 June 2017 - Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, is pleased to announce it filed a 510(k) submission for its NBT® system for the treatment of Major Depressive Disorder (MDD) with the US FDA on June 26, 2017.
MDD is a recurrent and frequently chronic disorder affecting 2-5% of the population in developed countries. Current treatment options involving pharmacologic agents and psychotherapy are sub-optimal, with 20-40% of patients gaining insufficient benefit. Neuro-stimulation, by repetitive Transcranial Magnetic Stimulation (TMS) has been shown to be effective in treating depression in patients who have failed pharmacologic treatment.
More info on Nexstim's website.
Next > Changes in Nexstim Plc's Management Team
Previous > Avantium included in Small Cap index Euronext